Toll-like receptor 4 in COVID-19: friend or foe?-Reference-Cited by-同舟云学术

Toll-like receptor 4 in COVID-19: friend or foe?

Published:2022-07 Issue:7 Volume:17 Page:415-417
ISSN:1746-0794
Container-title:Future Virology
language:en
Short-container-title:Future Virology

Author:

Mukherjee Suprabhat¹^ORCID

Affiliation:

1. Integrative Biochemistry & Immunology Laboratory, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal, 713340, India

Abstract

Tweetable abstract Toll-like receptor 4, an innate immune sensor, is one of the key ‘fate-deciding’ regulators of immunity as well as COVID-19 immunopathogenesis. Suitable targeting of Toll-like receptor 4 appears to be an effective strategy to counteract the pandemic.

Publisher

Future Medicine Ltd

Subject

Virology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fvl-2021-0249

Reference17 articles.

1. In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs

2. Chemotherapy vs. Immunotherapy in combating nCOVID19: An update

3. TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review

4. Toll‐like receptor polymorphism in host immune response to infectious diseases: A review

5. SARS-CoV-2 spike protein interacts with and activates TLR41

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections;Journal of Inflammation Research;2024-07

2. Multi-Omics Profiling Reveals Phenotypic and Functional Heterogeneity of Neutrophils in COVID-19;International Journal of Molecular Sciences;2024-03-29

3. In silico investigation of potential COVID-19-associated microRNA signatures;Cukurova Medical Journal;2024-03-29

4. Clinical and immunological features of COVID‐19 in patients with anti‐MDA5 dermatomyositis during the omicron wave in Chongqing, China;Journal of Medical Virology;2024-03

5. Comment on “The association of sickle cell disorder with adverse outcomes in COVID‐19 patients: A meta‐analysis”;Journal of Medical Virology;2024-03